News | June 26, 2025
Philogen withdraws marketing authorization application for Nidlegy in EU
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
25 women students to receive internship, training, and mentorship in Life Sciences segment
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Findings likely to generate hypotheses about potential new uses of drugs
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Biocon Biologics remains committed to global standards of quality and compliance
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Subscribe To Our Newsletter & Stay Updated
